RNS Number : 8773I
Cryo-Save Group NV
19 March 2010
19 March 2010
Cryo-Save Group N.V.
Non-Executive Director appointment
Cryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save" or "the Group"), Europe's leading stem cell bank, announces that Dr. Ronald H.W. Lorijn will be appointed as Non-Executive Director with effect from Cryo-Save's AGM, which is expected to be on 19 May 2010, subject to shareholder approval.
As Chief Executive of AMT NV (Amsterdam), Dr. Lorijn (MD, PhD, MBA) developed AMT from a small, one-product operation into a leading gene therapy company listed on the NYSE Euronext. Dr. Lorijn retired from AMT in February 2009. Previous to AMT, Dr. Lorijn was a member of Amgen, a leading human therapeutics company, where he was part of Amgen Europe's executive management team and responsible for its Clinical Operations, Business Development & Governmental Affairs.
Before joining Amgen he was Chief Medical Officer and Senior Director of Clinical Operations & Medical Affairs, Europe at Centocor after having been employed by the pharmaceutical division of AKZO (Organon), as its head of worldwide Medical Services and Product Surveillance.
Dr. Lorijn graduated from the Radboud University Nijmegen, completed a Ph.D. and was a certified obstetrician/gynaecologist before joining the biotech industry.
Marc Waeterschoot, Chief Executive, commented:
"I am very pleased that Ronald has accepted the invitation to join our Board. With his wide experience in the life-sciences business with internationally operating and fast growing companies, he will certainly contribute to the further successful execution of our strategy."
Further information required to be disclosed in respect of the above appointment pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies, is as follows: Dr. Ronald Hans Wilmar Lorijn, age 58, is a director of LxpR (a private company) and until February 2009 was Chief Executive of AMT N.V. Dr. Lorijn does not hold shares in Cryo-Save.
For further details:
Cryo-Save Group + 31 (0) 575 548 998
Marc Waeterschoot, Chief Executive
Arnoud van Tulder, Chief Financial Officer
Daniel Stewart & Company plc + 44 (0) 20 7776 6550
Simon Leathers / Emma Earl
College Hill + 44 (0) 20 7457 2020
Adrian Duffield/Rozi Morris
About Cryo-Save
With more than 120,000 samples saved, Cryo-Save is the leading stem cell bank in Europe and one of the fastest growing in the world. Driven by its international business strategy, Cryo-Save is now represented in 38 countries on three continents and has state-of-the-art processing facilities in Belgium, Germany, Dubai, India and France (under construction).
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to make an important contribution to conquer possible life-threatening diseases in the future. As a service to the public, Cryo-Save offers a Cost-free Family Donation Programme, free of charge, to families wishing to store their newborn's umbilical cord blood stem cells for a family member diagnosed with a life-threatening disease treatable by stem cells. The company is committed to further improve stem cell cryopreservation techniques, by participating in European Commission funded projects, in Universities and Hospitals.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAZKLFFBXFBBBD
